VistaGen Therapeutics, Inc. (VTGN): Price and Financial Metrics
VTGN Price/Volume Stats
| Current price | $2.57 | 52-week high | $33.45 |
| Prev. close | $2.71 | 52-week low | $2.30 |
| Day low | $2.50 | Volume | 209,051 |
| Day high | $2.92 | Avg. volume | 186,160 |
| 50-day MA | $4.01 | Dividend yield | N/A |
| 200-day MA | $4.50 | Market Cap | 18.77M |
VTGN Stock Price Chart Interactive Chart >
VTGN Stock Summary
- VTGN has a higher market value than only 10.42% of US stocks; more precisely, its current market capitalization is $29,170,428.
- VISTAGEN THERAPEUTICS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 7.84% of US listed stocks.
- As for revenue growth, note that VTGN's revenue has grown -124.07% over the past 12 months; that beats the revenue growth of only 0.43% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to VISTAGEN THERAPEUTICS INC are LVTX, SYRS, GSIT, DBVT, and IKNA.
- Visit VTGN's SEC page to see the company's official filings. To visit the company's web site, go to www.vistagen.com.
VTGN Valuation Summary
- In comparison to the median Healthcare stock, VTGN's EV/EBIT ratio is 100.83% lower, now standing at -0.1.
- VTGN's EV/EBIT ratio has moved up 0.1 over the prior 86 months.
Below are key valuation metrics over time for VTGN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| VTGN | 2023-05-23 | -79.7 | 1.4 | -0.5 | -0.1 |
| VTGN | 2023-05-22 | -82.4 | 1.5 | -0.5 | -0.1 |
| VTGN | 2023-05-19 | -83.2 | 1.5 | -0.5 | -0.1 |
| VTGN | 2023-05-18 | -85.4 | 1.5 | -0.5 | -0.1 |
| VTGN | 2023-05-17 | -87.4 | 1.5 | -0.5 | -0.2 |
| VTGN | 2023-05-16 | -84.3 | 1.5 | -0.5 | -0.1 |
VTGN Growth Metrics
- Its 4 year cash and equivalents growth rate is now at -53.61%.
- Its 3 year price growth rate is now at 46.48%.
- Its 5 year cash and equivalents growth rate is now at -53.61%.
The table below shows VTGN's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-12-31 | -0.3639 | -57.8309 | -63.7091 |
| 2022-09-30 | -0.1856 | -59.9431 | -64.6911 |
| 2022-06-30 | 1.0649 | -55.0519 | -60.3775 |
| 2022-03-31 | 1.1089 | -45.2565 | -48.7075 |
| 2021-12-31 | 1.5119 | -34.9499 | -61.579 |
| 2021-09-30 | 1.4676 | -27.893 | -56.4881 |
VTGN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- VTGN has a Quality Grade of C, ranking ahead of 36.05% of graded US stocks.
- VTGN's asset turnover comes in at 0.017 -- ranking 376th of 682 Pharmaceutical Products stocks.
- SAGE, SVRA, and EDIT are the stocks whose asset turnover ratios are most correlated with VTGN.
The table below shows VTGN's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.017 | 1 | -4.522 |
| 2021-03-31 | 0.018 | 1 | -3.130 |
| 2020-12-31 | 0.018 | 1 | -2.501 |
| 2020-09-30 | 0.036 | 1 | -2.651 |
| 2020-06-30 | 0.000 | NA | -3.134 |
| 2020-03-31 | 0.000 | NA | -3.789 |
VTGN Price Target
For more insight on analysts targets of VTGN, see our VTGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $7.00 | Average Broker Recommendation | 1.12 (Strong Buy) |
VistaGen Therapeutics, Inc. (VTGN) Company Bio
VistaGen Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company develops products for patients with diseases and disorders involving the central nervous system. VistaGen Therapeutics serves customers in the United States.
Latest VTGN News From Around the Web
Below are the latest news stories about VISTAGEN THERAPEUTICS INC that investors may wish to consider to help them evaluate VTGN as an investment opportunity.
Vistagen to Present at Jefferies 2023 Global Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., June 06, 2023--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that its Chief Executive Officer, Shawn Singh, will present and host one-on-one meetings at the Jefferies Global Healthcare Conference taking place June 7 – 9, 2023 in New York City, NY. |
Vistagen Announces Stockholder-Approved Reverse Stock SplitSOUTH SAN FRANCISCO, Calif., June 06, 2023--Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that it will implement a stockholder-approved reverse stock split of its outstanding shares of common stock, at a ratio of one-for-thirty unanimously approved by its Board of Directors. Vistagen common stock will begin trading |
Vistagen Presents Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual MeetingSOUTH SAN FRANCISCO, Calif., June 01, 2023--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that positive safety and exploratory efficacy data from its large Phase 3 open-label study of fasedienol (PH94B) nasal spray for the treatment of anxiety in adults with social anxiety disorder (SAD) were presented in a late-b |
Vistagen to Present Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual MeetingSOUTH SAN FRANCISCO, Calif., May 30, 2023--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that safety and exploratory efficacy data from its Phase 3 open-label study of fasedienol (PH94B) nasal spray for the treatment of adults with social anxiety disorder (SAD) will be presented in a late-breaking poster presentat |
Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental HealthSOUTH SAN FRANCISCO, Calif., May 24, 2023--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that it has been recognized by Mental Health America (MHA) for its commitment to fostering mental health and well-being in the workplace. Vistagen’s supportive workplace culture, mental health care benefits, focus on inclusion |
VTGN Price Returns
| 1-mo | -35.97% |
| 3-mo | -36.12% |
| 6-mo | -26.78% |
| 1-year | -92.21% |
| 3-year | -83.37% |
| 5-year | -94.21% |
| YTD | -16.83% |
| 2022 | -94.72% |
| 2021 | 0.52% |
| 2020 | 181.28% |
| 2019 | -54.02% |
| 2018 | 35.14% |
Loading social stream, please wait...